OwnershipPublicly listed · NYSE: DNASEC EDGAR company record and tickers file (NYSE: DNA) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as NYSE: DNA, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
5developments published
$167MUS federal obligations on record
13federal awards
Aug 5, 2026latest development
Timeline
- Aug 5, 2026 · Reported results
Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland
Company-reported - Jul 30, 2026 · Reported results
Ginkgo Bioworks Announces Date of Second Quarter 2026 Results Presentation
Company-reported - Jun 11, 2026 · Shareholder vote
Ginkgo Bioworks reports results of a shareholder vote (Form 8-K, Item 5.07)
Regulatory filing - May 7, 2026 · Reported results
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Company-reported - May 3, 2026 · Government award
Centers for Disease Control and Prevention obligates $3.2 million to Ginkgo Bioworks
Government record
Profile
- Legal name
- Ginkgo Bioworks Holdings, Inc.
- Listing
- NYSE DNA
- SEC filer
- CIK 0001830214 ↗
- SEC industry code
- Biological Products, (No Diagnostic Substances)
- Incorporated
- DE
- Coverage
- Filings + federal awards
Mix of developments
Watch Ginkgo Bioworks
Anything new from Ginkgo Bioworks lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digestUS federal awards
From USAspending.gov. Obligated is money the government has committed, not company revenue and not the contract’s potential ceiling. Outlays is what has actually been paid. Totals: $167 million obligated, $93.0 million paid out across 13 awards.
| Agency | Description | Obligated | Paid out | Period | Record |
|---|---|---|---|---|---|
| Centers for Disease Control and Prevention | TRAVELER-BASED GENOMIC SURVEILLANCE PROGRAM | $78.0 million | $22.9 million | Feb 28, 2025 – Mar 21, 2028 | USAspending ↗ |
| Centers for Disease Control and Prevention | AIRPORT GENOMIC TESTING | $62.6 million | $62.5 million | Aug 16, 2022 – Mar 21, 2025 | USAspending ↗ |
| Defense Advanced Research Projects Agency | DARPA ICE CONTROL FOR COLD ENVIRONMENTS (ICE) | $5.2 million | Not stated | Jan 26, 2024 – Aug 19, 2026 | USAspending ↗ |
| Department of the Army | DARPA CONTRACT AWARD (BASE) "SUPERB: SYNBIO + UNIVERSAL PURIFICATION OF EXTRACT-DERIVED, RIGHT-ON-TIME BIOLOGICS" | $4.8 million | $1.3 million | Dec 15, 2022 – Feb 29, 2024 | USAspending ↗ |
| Centers for Disease Control and Prevention | TEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQ | $3.8 million | $2.3 million | Sep 6, 2024 – Sep 5, 2027 | USAspending ↗ |
| Department of the Army | COOPERATIVE AGREEMENT | $3.4 million | $623,191 | Jan 29, 2024 – Dec 31, 2026 | USAspending ↗ |
| Centers for Disease Control and Prevention | METAGENOMIC NEXT-GENERATION SEQUENCING (MNGS) | $3.2 million | $479,984 | May 3, 2026 – Apr 14, 2028 | USAspending ↗ |
| Department of the Navy | DNA RECORDING INTRINSIC CELLULAR BIOINTELLIGENCE (DRINC BIO) | $1.8 million | Not stated | May 2, 2023 – May 21, 2025 | USAspending ↗ |
Showing the 8 largest of 13 awards on record.